{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 38,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/9",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.36,
        "y": 0.35
      },
      "kind": "image",
      "text": "Genelux, Amgen, Replimune, CG Oncology, Daiichi-Sankyo, Oncolytics Biotech",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00d8261a-475b-4bc0-8f0c-599cb064da7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "list",
      "text": "Target & Treat Metastatic Disease; Systemic Delivery and redosing; Robust Immune Activation Profile; Target & Treat Tumors of Various Size",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "517e2cf0-8214-4924-8d53-783b4674b88a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "list",
      "text": "Broad spectrum of activity; Tumor selectivity; Strong lytic activity / spread; Strong immune activator; Engineering capability; Multiple routes of delivery; Nonhuman pathogen; Stable DNA virus; Cytoplasmic, no genomic integration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dda86efa-d699-486a-8e77-049f00555a02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.35,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "IV dosing is the physician preferred administration technique, and our IV data has the potential to enable physician preferred administration vs. local-delivery-only assets",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65ca8180-d811-4542-969a-b6fe359a3bdd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Competitive Advantages of Olvi-Vec as an Oncolytic Virus",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bb4f1be-2c86-4c7d-bb21-0eeffd6ed43a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "competitive-advantage",
      "slug": null,
      "matchId": "ffda6a9f-4efe-4456-8275-f0781e9d74d4",
      "evidence": "Comparison of Olvi-Vec against other oncolytic virus assets",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 4,
      "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5",
      "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.",
      "position": 0,
      "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}